Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Millions		Jun. 28, 2015	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		$ 7,642	$ 7,660
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross Carrying Amount		73,186	73,887
Finite-lived Intangible Assets, Accumulated Amortization	[1]	(47,403)	(46,381)
Finite-lived Intangible Assets, less Accumulated Amortization		25,782	27,506
Intangible assets, gross carrying amount	[1]	80,827	81,547
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2]	33,424	35,166
Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		7,208	7,273
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		434	387
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross Carrying Amount		70,226	70,946
Finite-lived Intangible Assets, Accumulated Amortization		(45,611)	(44,694)
Finite-lived Intangible Assets, less Accumulated Amortization		24,615	26,252
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross Carrying Amount		1,905	1,951
Finite-lived Intangible Assets, Accumulated Amortization		(890)	(855)
Finite-lived Intangible Assets, less Accumulated Amortization		1,015	1,096
License Agreements and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross Carrying Amount		1,054	991
Finite-lived Intangible Assets, Accumulated Amortization		(902)	(832)
Finite-lived Intangible Assets, less Accumulated Amortization		$ 152	$ 159

[1] The decrease in identifiable intangible assets, less accumulated amortization, is primarily related to amortization, partially offset by assets acquired as part of the acquisition of Baxter’s portfolio of marketed vaccines. For information about the assets acquired as part of the acquisition of Baxter’s portfolio of marketed vaccines, see Note 2A.

[2] Amounts may not add due to rounding.